Bruce Luxon, MD, PhD is chairman and chief of service for the Department of Medicine at Georgetown University Hospital, Washington. His clinical focus is in hepatology, with expertise in autoimmune hepatitis, cholestatic liver diseases and viral hepatitis, including hepatitis B and C.

Carolin Lackner is a Professor of Pathology at the Medical University of Graz, Austria. She is specialized in hepatopathology with particular interest in steatotic liver diseases and serves as a central pathologist in clinical trials of MASH.

Nikhil Kalita holds degrees from accelerated programs at the George Washington University. He joined the UC San Diego Health MASLD Research Center in June 2024. His work focuses on coordinating clinical research studies on non-invasive diagnostics of liver disease, focusing on patients with diabetes, cirrhosis, and MASLD. He also contributes to literature reviews and analyzes clinical and national datasets like NHANES to support ongoing research.

Ludovic Saba is a second-year internal medicine resident at UT Southwestern Medical Center in Dallas, TX. He is interested in pursuing a fellowship in gastroenterology and hepatology. His research focuses on metabolic dysfunction-associated steatotic liver disease (MASLD), alcoholic liver disease, and healthcare disparities. Prior to residency, Dr. Saba completed two years of clinical outcomes research at the Cleveland Clinic Florida.

I am a consultant in Hepatology and Professor of Practice in Metabolic Liver Diseases at Imperial College London. My area of expertise, includes MASLD.

I am the Director of the Liver Research Program at the University of Illinois Chicago. I am actively involved in the Center for Alcohol Research, in the T32 Training Grants from the Cancer Center and the Department of Endocrinology, and in mentoring Graduate students and Postdoctoral fellows. In addition, I hold leadership roles at the American Association for the Studies of Liver Diseases (Steering Committee, Liver Fibrosis SIG) and the International Society for the Hepatic Sinusoid Research (2022-2024 President-Elect).

I am an Associate Professor at University of Kansas Medical Center. My research focuses on epigenetic changes in the liver induced by exposure to alcohol and their role in disease progression and resolution.

I am a physician-scientist at Yale University with a research interest in alcohol-associated liver disease. Our lab studies the pathogenesis of alcohol-associated hepatitis and the ways of liver resident cells interact with immune cells.

Daniel Legg is the U.S. Early Asset Lead for the CardioRenal and Metabolic therapeutic area and Clinical Development Lead for liver disease at Boehringer Ingelheim. He is passionate about advancing science to address unmet medical needs and is honored to share insights on early asset development and clinical strategy at AASLD.